Reema Jasuja, PhD, is a Principle Scientist in Pfizer’s Rare Disease Research Unit. Dr. Jasuja did her graduate work in molecular and cellular pharmacology at University of Wisconsin- Madison with Dr. Daniel Greenspan. She studied extracellular signaling regulation of Bone morphogenetic protein 1 and how the prodomain of Bone morphogenetic protein 1regulates the protein activity to affect downstream signaling mechanisms. Her postdoctoral work at the Beth Israel Deaconess Medical Center, Harvard Medical School with Drs. Barbara and Bruce Furie.
Reema Jasuja has broad interests in the hematology projects across the Rare Disease Research Unit, including sickle cell disease and haemophilia; hemostasis and thrombosis regulation by extracellular protein disulfide isomerase and other thiol isomerases